Last reviewed 2026-04-22 · How we verify

DWJ211

DWJ211 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.

DWJ211 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

By simultaneously activating GLP-1 and GIP receptors, DWJ211 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater improvements in blood glucose control and body weight reduction compared to single GLP-1 agonists, with a favorable metabolic profile.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Gastrointestinal disorders

Key clinical trials

• Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (PHASE2)
• Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (PHASE3)
• Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DWJ211 CI brief — competitive landscape report
• DWJ211 updates RSS · CI watch RSS
• Daewoong Pharmaceutical Co. LTD. portfolio CI